These findings reveal that targeting IL-12 could be a potential therapeutic approach for restricting TET2-mutant CH in the background of an existing JAK2V617F-mutant driven MPN to minimize future risk of disease progression to pAML (Figure 5M). Here, TET2 is linked to myeloproliferative neoplasm.